Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia
Aplastic anemia (AA) is most frequently due to autoimmune attack on its own stem cells. Alemtuzumab is a monoclonal antibody which recognizes the CD52 antigen on the surface of T and B cells. It has proved useful in autoimmune diseases, lymphoproliferative conditions, and graft versus host disease....
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2010-03, Vol.89 (3), p.299-303 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 303 |
|---|---|
| container_issue | 3 |
| container_start_page | 299 |
| container_title | Annals of hematology |
| container_volume | 89 |
| creator | Gómez-Almaguer, David Jaime-Pérez, José Carlos Garza-Rodríguez, Verónica Chapa-Rodríguez, Adrián Tarín-Arzaga, Luz Herrera-Garza, José Luís Ruiz-Argüelles, Guillermo J López-Otero, Avril González-Llano, Oscar Rodríguez-Romo, Laura |
| description | Aplastic anemia (AA) is most frequently due to autoimmune attack on its own stem cells. Alemtuzumab is a monoclonal antibody which recognizes the CD52 antigen on the surface of T and B cells. It has proved useful in autoimmune diseases, lymphoproliferative conditions, and graft versus host disease. Based on its immunosuppressive properties, we treated 14 AA patients with alemtuzumab. Median age was 23 years. Ten milligrams of alemtuzumab were injected subcutaneously each day for five consecutive days. Cyclosporine A was also administered orally at a dose of 2 mg/kg every 12 h for 3 months, and then gradually tapered. Response to alemtuzumab was followed for a median of 20 months. There were eight responses (57.1%), two complete and six partial. Whereas six (42.8%) patients were non-responders. Median complete blood count values on alemtuzumab responders were Hb 13.1 mg/dL, absolute neutrophil count 2.4 × 10⁹/L, and platelets 97.5 × 10⁹/L. A good response was produced in 57% of AA patients with the administration of alemtuzumab, who lacked a stem cell donor. |
| doi_str_mv | 10.1007/s00277-009-0816-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733688846</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1944387001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-8223836869f5fa6838a1b0f5fe3317effd1121103d609f2ff4e01b337546c4f43</originalsourceid><addsrcrecordid>eNp9kEtP3TAQha2qCC6UH9BNibphFTpjO34sESoPCYkFZW05uTYNSuJgO4vLr69RroTEot7YGn_nzMwh5DvCBQLIXwmASlkD6BoUirr5QjbIGa2hUfwr2YBmum7KOSLHKb0AIFWcHpIj1BIaRLEhD49L2y3ZTi4sqbKDG_Pytoy2reahFLpdN4Q0h9hPrvIhVvmvq3J0No9uylXwlZ0Hm3LfVcVi7O03cuDtkNzp_j4hT9e__1zd1vcPN3dXl_d1xzTPtaKUKSaU0L7xViimLLZQ3o4xlM77LSJFBLYVoD31njvAljHZcNFxz9kJOV995xheF5eyGfvUuWFYNzGSFXeluCjkz0_kS1jiVIYzFHVpIlAWCFeoiyGl6LyZYz_auDMI5j1rs2ZtStbmPWvTFM2PvfHSjm77odiHWwC6Aql8Tc8ufnT-n-vZKvI2GPsc-2SeHikgA5Saa5DsH4yQkh4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219211617</pqid></control><display><type>article</type><title>Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Gómez-Almaguer, David ; Jaime-Pérez, José Carlos ; Garza-Rodríguez, Verónica ; Chapa-Rodríguez, Adrián ; Tarín-Arzaga, Luz ; Herrera-Garza, José Luís ; Ruiz-Argüelles, Guillermo J ; López-Otero, Avril ; González-Llano, Oscar ; Rodríguez-Romo, Laura</creator><creatorcontrib>Gómez-Almaguer, David ; Jaime-Pérez, José Carlos ; Garza-Rodríguez, Verónica ; Chapa-Rodríguez, Adrián ; Tarín-Arzaga, Luz ; Herrera-Garza, José Luís ; Ruiz-Argüelles, Guillermo J ; López-Otero, Avril ; González-Llano, Oscar ; Rodríguez-Romo, Laura</creatorcontrib><description>Aplastic anemia (AA) is most frequently due to autoimmune attack on its own stem cells. Alemtuzumab is a monoclonal antibody which recognizes the CD52 antigen on the surface of T and B cells. It has proved useful in autoimmune diseases, lymphoproliferative conditions, and graft versus host disease. Based on its immunosuppressive properties, we treated 14 AA patients with alemtuzumab. Median age was 23 years. Ten milligrams of alemtuzumab were injected subcutaneously each day for five consecutive days. Cyclosporine A was also administered orally at a dose of 2 mg/kg every 12 h for 3 months, and then gradually tapered. Response to alemtuzumab was followed for a median of 20 months. There were eight responses (57.1%), two complete and six partial. Whereas six (42.8%) patients were non-responders. Median complete blood count values on alemtuzumab responders were Hb 13.1 mg/dL, absolute neutrophil count 2.4 × 10⁹/L, and platelets 97.5 × 10⁹/L. A good response was produced in 57% of AA patients with the administration of alemtuzumab, who lacked a stem cell donor.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-009-0816-5</identifier><identifier>PMID: 19705116</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Adolescent ; Adult ; Aged ; Alemtuzumab ; Anemia, Aplastic - drug therapy ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized ; Antibodies, Neoplasm - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Child ; Cyclosporine - administration & dosage ; Female ; Follow-Up Studies ; Hematology ; Humans ; Immunosuppressive Agents - therapeutic use ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Remission Induction ; Survival Analysis ; Treatment Outcome ; Young Adult</subject><ispartof>Annals of hematology, 2010-03, Vol.89 (3), p.299-303</ispartof><rights>Springer-Verlag 2009</rights><rights>Springer-Verlag 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c394t-8223836869f5fa6838a1b0f5fe3317effd1121103d609f2ff4e01b337546c4f43</citedby><cites>FETCH-LOGICAL-c394t-8223836869f5fa6838a1b0f5fe3317effd1121103d609f2ff4e01b337546c4f43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-009-0816-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-009-0816-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19705116$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gómez-Almaguer, David</creatorcontrib><creatorcontrib>Jaime-Pérez, José Carlos</creatorcontrib><creatorcontrib>Garza-Rodríguez, Verónica</creatorcontrib><creatorcontrib>Chapa-Rodríguez, Adrián</creatorcontrib><creatorcontrib>Tarín-Arzaga, Luz</creatorcontrib><creatorcontrib>Herrera-Garza, José Luís</creatorcontrib><creatorcontrib>Ruiz-Argüelles, Guillermo J</creatorcontrib><creatorcontrib>López-Otero, Avril</creatorcontrib><creatorcontrib>González-Llano, Oscar</creatorcontrib><creatorcontrib>Rodríguez-Romo, Laura</creatorcontrib><title>Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Aplastic anemia (AA) is most frequently due to autoimmune attack on its own stem cells. Alemtuzumab is a monoclonal antibody which recognizes the CD52 antigen on the surface of T and B cells. It has proved useful in autoimmune diseases, lymphoproliferative conditions, and graft versus host disease. Based on its immunosuppressive properties, we treated 14 AA patients with alemtuzumab. Median age was 23 years. Ten milligrams of alemtuzumab were injected subcutaneously each day for five consecutive days. Cyclosporine A was also administered orally at a dose of 2 mg/kg every 12 h for 3 months, and then gradually tapered. Response to alemtuzumab was followed for a median of 20 months. There were eight responses (57.1%), two complete and six partial. Whereas six (42.8%) patients were non-responders. Median complete blood count values on alemtuzumab responders were Hb 13.1 mg/dL, absolute neutrophil count 2.4 × 10⁹/L, and platelets 97.5 × 10⁹/L. A good response was produced in 57% of AA patients with the administration of alemtuzumab, who lacked a stem cell donor.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Alemtuzumab</subject><subject>Anemia, Aplastic - drug therapy</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antibodies, Neoplasm - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Child</subject><subject>Cyclosporine - administration & dosage</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Remission Induction</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kEtP3TAQha2qCC6UH9BNibphFTpjO34sESoPCYkFZW05uTYNSuJgO4vLr69RroTEot7YGn_nzMwh5DvCBQLIXwmASlkD6BoUirr5QjbIGa2hUfwr2YBmum7KOSLHKb0AIFWcHpIj1BIaRLEhD49L2y3ZTi4sqbKDG_Pytoy2reahFLpdN4Q0h9hPrvIhVvmvq3J0No9uylXwlZ0Hm3LfVcVi7O03cuDtkNzp_j4hT9e__1zd1vcPN3dXl_d1xzTPtaKUKSaU0L7xViimLLZQ3o4xlM77LSJFBLYVoD31njvAljHZcNFxz9kJOV995xheF5eyGfvUuWFYNzGSFXeluCjkz0_kS1jiVIYzFHVpIlAWCFeoiyGl6LyZYz_auDMI5j1rs2ZtStbmPWvTFM2PvfHSjm77odiHWwC6Aql8Tc8ufnT-n-vZKvI2GPsc-2SeHikgA5Saa5DsH4yQkh4</recordid><startdate>20100301</startdate><enddate>20100301</enddate><creator>Gómez-Almaguer, David</creator><creator>Jaime-Pérez, José Carlos</creator><creator>Garza-Rodríguez, Verónica</creator><creator>Chapa-Rodríguez, Adrián</creator><creator>Tarín-Arzaga, Luz</creator><creator>Herrera-Garza, José Luís</creator><creator>Ruiz-Argüelles, Guillermo J</creator><creator>López-Otero, Avril</creator><creator>González-Llano, Oscar</creator><creator>Rodríguez-Romo, Laura</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20100301</creationdate><title>Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia</title><author>Gómez-Almaguer, David ; Jaime-Pérez, José Carlos ; Garza-Rodríguez, Verónica ; Chapa-Rodríguez, Adrián ; Tarín-Arzaga, Luz ; Herrera-Garza, José Luís ; Ruiz-Argüelles, Guillermo J ; López-Otero, Avril ; González-Llano, Oscar ; Rodríguez-Romo, Laura</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-8223836869f5fa6838a1b0f5fe3317effd1121103d609f2ff4e01b337546c4f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Alemtuzumab</topic><topic>Anemia, Aplastic - drug therapy</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antibodies, Neoplasm - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Child</topic><topic>Cyclosporine - administration & dosage</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Remission Induction</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gómez-Almaguer, David</creatorcontrib><creatorcontrib>Jaime-Pérez, José Carlos</creatorcontrib><creatorcontrib>Garza-Rodríguez, Verónica</creatorcontrib><creatorcontrib>Chapa-Rodríguez, Adrián</creatorcontrib><creatorcontrib>Tarín-Arzaga, Luz</creatorcontrib><creatorcontrib>Herrera-Garza, José Luís</creatorcontrib><creatorcontrib>Ruiz-Argüelles, Guillermo J</creatorcontrib><creatorcontrib>López-Otero, Avril</creatorcontrib><creatorcontrib>González-Llano, Oscar</creatorcontrib><creatorcontrib>Rodríguez-Romo, Laura</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gómez-Almaguer, David</au><au>Jaime-Pérez, José Carlos</au><au>Garza-Rodríguez, Verónica</au><au>Chapa-Rodríguez, Adrián</au><au>Tarín-Arzaga, Luz</au><au>Herrera-Garza, José Luís</au><au>Ruiz-Argüelles, Guillermo J</au><au>López-Otero, Avril</au><au>González-Llano, Oscar</au><au>Rodríguez-Romo, Laura</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2010-03-01</date><risdate>2010</risdate><volume>89</volume><issue>3</issue><spage>299</spage><epage>303</epage><pages>299-303</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Aplastic anemia (AA) is most frequently due to autoimmune attack on its own stem cells. Alemtuzumab is a monoclonal antibody which recognizes the CD52 antigen on the surface of T and B cells. It has proved useful in autoimmune diseases, lymphoproliferative conditions, and graft versus host disease. Based on its immunosuppressive properties, we treated 14 AA patients with alemtuzumab. Median age was 23 years. Ten milligrams of alemtuzumab were injected subcutaneously each day for five consecutive days. Cyclosporine A was also administered orally at a dose of 2 mg/kg every 12 h for 3 months, and then gradually tapered. Response to alemtuzumab was followed for a median of 20 months. There were eight responses (57.1%), two complete and six partial. Whereas six (42.8%) patients were non-responders. Median complete blood count values on alemtuzumab responders were Hb 13.1 mg/dL, absolute neutrophil count 2.4 × 10⁹/L, and platelets 97.5 × 10⁹/L. A good response was produced in 57% of AA patients with the administration of alemtuzumab, who lacked a stem cell donor.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>19705116</pmid><doi>10.1007/s00277-009-0816-5</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2010-03, Vol.89 (3), p.299-303 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733688846 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adolescent Adult Aged Alemtuzumab Anemia, Aplastic - drug therapy Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antibodies, Neoplasm - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Child Cyclosporine - administration & dosage Female Follow-Up Studies Hematology Humans Immunosuppressive Agents - therapeutic use Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Remission Induction Survival Analysis Treatment Outcome Young Adult |
| title | Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T18%3A56%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Subcutaneous%20alemtuzumab%20plus%20cyclosporine%20for%20the%20treatment%20of%20aplastic%20anemia&rft.jtitle=Annals%20of%20hematology&rft.au=G%C3%B3mez-Almaguer,%20David&rft.date=2010-03-01&rft.volume=89&rft.issue=3&rft.spage=299&rft.epage=303&rft.pages=299-303&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-009-0816-5&rft_dat=%3Cproquest_cross%3E1944387001%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219211617&rft_id=info:pmid/19705116&rfr_iscdi=true |